Loading
A phase 1/2 trial of ET140203 T Cells in hepatoblastoma and hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT04634357 by Eureka Therapeutics Inc., with 12 participants planned, started 2022-07-19 and due to reach its primary completion in 2027-12-31. Interventions recorded: ET140203 T Cells.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eureka Therapeutics, Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/